Astellas, Pfizer agree to co-promote Caduet

More co-promotion for Astellas Pharma. The Japanese company inked a deal with Pfizer to promote the latter's combo cardiovascular drug Caduet. Pfizer will make and sell the drug, which puts the blood-pressure treatment Norvasc and cholesterol drug Lipitor in one tablet. Astellas and Pfizer will promote the drug together; Pfizer will book sales and Astellas will get a fee.

Earlier this month, Astellas made a deal with AstraZeneca to co-promote the asthma drug Symbicort. AstraZeneca is already looking for government approval of the drug in Japan; once it's OK'd for the market, Astellas will handle sales through its already established channels, and the two companies will both promote the product. 

- see the Astellas release

Related Articles:
Astellas reorganizes R&D ops
Astellas drops bid for CV Therapeutics

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.